Reuters: Health
AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.
AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer
AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer
Reuters: Health
AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.
Reuters: Health
AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment